RobsonM, LevinD, FedericiJ, et al. Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations. J Natl Cancer Inst1999; 91: 2112–2117.
RobsonME, ChappuisPO, SatagopanJ, WongN, BoydJ, GoffinJR, HudisC, RobergeD, NortonL, BeginLR, OffitK, FoulkesWD. A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment. Breast Cancer Res2004; 6(1): R8–R17.
HafftyBG, HarroldE, KnanAJ, et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet2002; 359: 1471–1477.
FisherB, AndersonS, BryantJ, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. New Engl J Med2002; 347: 1233–1241.
VeronesiU, CascinelliN, MarianiL, et al. Twenty-year follow-up of a randomized study comparing breast- conserving surgery with radical mastectomy for early breast cancer. New Engl J Med2002; 347: 1227–1232.
ClausEB, SchildkrantJM, ThompsonWD, et al. The genetic attributable risk of breast and ovarian cancer. Cancer1996; 77: 2318–2324.
XiaF, PowellS. The molecular basis of radiosensitivity and chemosensitivity in the treatment of breast cancer. Semin Radiat Oncol2002; 12: 296–304.
HallJM, LeeMK, NewmanB, et al. Linkage of early onset familial breast cancer to chromosome 17q21. Science1990; 250: 1684–1689.
WoosterR, NeuhausenSL, MangionJ, et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science1994; 265: 2088–2090.
BuchholzTA, WazerDE. Molecular biology and genetics of breast cancer development: a clinical perspective. Semin Radiat Oncol2002: 12: 285–295.
ZhongQ, ChenCF, LiS, et al. Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response. Science1999; 285: 747–750.
XuB, KimS, KastanMB. Involvement of BRCA1 in S-phase and G(2)-phase checkpoints after ionizing irradiation. Mol Cell Biol2001; 21: 3445–3450.
XuX, WeaverZ, LinkeSP, et al. Centrosome amplification and a defective G2-M cell cycle checkpoint induce genetic instability in BRCA1 exon 11 isoform-deficient cells. Mol Cell1999; 3: 389–395.
SharanSK, MorimatsuM, AlbrechtU, et al. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2. Nature1997; 386: 804–810.
ShenS, WeaverZ, XuX, et al. A targeted disruption of the murine BRCA1 gene causes γ-irradiation hypersensitivity and genetic instability. Oncogene1998; 17: 3115–3124.
PorterDE, CohenBB, WallaceMR, et al. Breast cancer incidence, penetrance, and survival in probable carriers of BRCA1 gene mutation in families linked to BRCA1 on chromosome 17q12-21. Br J Surg1994; 81: 1512–1515.
FordD, EastonDF, StrattonM, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families: The Breast Cancer Linkage Consortium. Am J Hum Genet1998; 62: 676–689.
JacquemierJ, EisingerF, BirnbaumD, et al. Histoprognostic grade in BRCA1-associated breast cancer. Lancet1995; 345: 1503.
MarcusJN, WatsonP, PageDL, et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer1996; 77: 697–709.
VerhoogLC, BrekelmansCTM, SeynaeveC, et al. Survival and tumor characteristics of breast-cancer patients with germline mutations of BRCA1. Lancet1998; 351: 316–321.
FordD, EastonDF, BishopDT, et al. Risks of cancer in BRCA1-mutation carriers. Lancet1994; 343: 692–695.
FordD, EastonDF. The genetics of breast an ovarian cancer. Br J Cancer1995; 72: 805–812.
CoxJD, StetzJ, PajakTF. Toxicity criteria of the Radiation Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys1995; 31: 1341–1346.
FisherB, ConstantinoJP, WickerhamDL, et al. Tamoxifen for prevention of breast cancer; report of the National Surgical Adjuvant Breast and Bowel Project P1 study. J Natl Cancer Inst1998; 90: 1371–1388.
RebbeckTR, LevinAM, EisenA, et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst1999; 91: 1475–1479.
RebbeckTR, LynchHT, NeuhausenSL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. New Engl J Med2002; 346: 1616–1622.
KauffND, SatagopanJM, RobsonME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. New Engl J Med2002; 346: 1609–1615.
KingM, WieandS, HaleK, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2. J Am Med Assoc2001; 286: 2251–2256.
NarodSA, BrunetJ, GhadirianP, et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case control study. Lancet2000; 356: 1876–1881.